# OnCo record paper-empower-lung-1-lancet-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-empower-lung-1-lancet-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-empower-lung-1-lancet-2021" ;
  schema:name "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial"@en ;
  schema:description "Published report from the EMPOWER-Lung 1 trial registered as NCT03088540, in The Lancet (2021), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-empower-lung-1-lancet-2021/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(21)00228-2>, <https://pubmed.ncbi.nlm.nih.gov/33581821/>, <https://europepmc.org/article/MED/33581821>, <https://clinicaltrials.gov/study/NCT03088540> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(21)00228-2> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Sezer A, Kilickap S, Gümüş M, et al." ;
  onco:trials <https://onco.cc/trials/empower-lung-1/> ;
  onco:journals <https://onco.cc/journals/lancet/> .